Bay Area's Global Blood Therapeutics Terminates Lung Disease Program Post author:Sam Post published:October 22, 2017 Post category:BioPharma The company is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF). Source: BioSpace You Might Also Like ImmusanT, Inc. Presents Data From Multiple Studies Supporting Continued Development Of Nexvax2 September 10, 2017 Meet the Little-Known Chinese CAR-T Biotech Up More Than 500% Since June 2017 February 13, 2018 ViewRay Rakes in $26.1 Million in Private Placement January 18, 2017
ImmusanT, Inc. Presents Data From Multiple Studies Supporting Continued Development Of Nexvax2 September 10, 2017